Outlook Therapeutics spent years chasing an ophthalmic label for a molecule retina specialists already inject every week. Late July the Food and Drug Administration approved LYTENAVA, an ophthalmic formulation of bevacizumab, as the first labeled bevacizumab product for wet age-related macular degeneration in the United States. That decision closed a three-letter regulatory fight and converted the equity from a binary filing story into a commercial-conversion story. The market is not treating the label as a franchise. The debate is whether a purpose-built vial can take share from cheap compounded Avastin before the balance sheet forces another raise.
Europe already offered a live test of that conversion. Net product revenue in the June quarter collapsed after returns reserves and wholesaler fees erased earlier shipments. Nine-month net revenue turned negative even as unit shipments continued in Germany, Austria, and the United Kingdom. Operating cash used over the nine months reached $43.8 million against mid-year cash of $11.2 million, which is why the August follow-on existed. The August sale priced stock and five-year warrants at $0.99 a unit. The approval arrived on a balance sheet that still carried a going-concern paragraph and an Atlas Sciences note due the following June.
Management now talks about a United States launch before year-end and a wholesale acquisition cost under $500 a vial. Peak domestic sales are framed above half a billion later this decade. First-year revenue sits in a $50 million to $75 million band. A permanent billing code is not expected until next spring. Those figures only work if retina practices abandon a cheap compounded syringe for a labeled product that costs several times more. The open question is whether the label converts the existing off-label habit, or whether the equity remains a repeatedly refinanced option on a market that already has the molecule.